“A major trial of a drug to treat mild dementia due to Alzheimer’s disease has ended in failure.” Eli Lilly’s solanezumab drug was one of the most anticipated drug developments for the Alzheimer community. The drug was in phase 3 of clinical trials when it got removed after revealing that patients didn’t experience a statistically significant difference in cognitive decline (memory loss). Eli Lilly decided to completely end the development of the drug, after having spent around $3 billion in dementia research over the past 25 years.
The end of solanezumab caused many repercussions on the topic of Alzheimer. Firstly, not only did Eli Lilly’s share prices tank, but other companies working on similar drugs saw their share prices tank as well. Investors lost their hope for Alzheimer drugs over Eli Lilly’s failure, showing just how much investors anticipated the development of solanezumab. More importantly though, is how the Alzheimer community was affected. If investors believe in Eli Lilly, it is hard to imagine how people affected with Alzheimer felt during the company’s setback. Effective Alzheimer treatments are still un-met, and the community strongly believe in this new drug to be the stepping-stone into treating the disease.
Although this is a big drawback in Alzheimer’s research, Jeremy Hughes, chief executive of the Alzheimer society is still hopeful.
“Dementia is society’s biggest health challenge – and we’ve seen time and again that developing effective treatments is incredibly difficult.”
“This is only one drug of several in the pipeline and they aim to tackle dementia in different ways, so we should not lose hope.
“Dementia can and will be beaten.”
Written by Alex Fridgant